Evidence map›Paper›PMID 37279855›Full record

Trial reportTransplantation and cellular therapy2023

Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.

Shernan G Holtan, Andrea Hoeschen, Qing Cao, Celalettin Ustun, Brian C Betts, Najla El Jurdi, Joseph Maakaron, Armin Rashidi, Jeffrey S Miller, John E Wagner and 5 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transplantation and cellular therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02525029 (Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02525029 phase1 / phase2completednot on this map

Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease

TypeinterventionalSponsorMasonic Cancer Center, University of MinnesotaRan2016 to 2022Enrolled53ConditionsGraft vs Host DiseaseArmsPregnyl®
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Shernan G HoltanBlood and Marrow Transplant & Cellular Therapy, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. Electronic address: sgholtan@umn.edu.
Andrea HoeschenClinical Trials Office, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Qing CaoBiostatistics and Informatics, Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota.
Celalettin UstunBlood and Marrow Transplant Program, Rush University, Chicago, Illinois.
Brian C BettsBlood and Marrow Transplant & Cellular Therapy, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Najla El JurdiBlood and Marrow Transplant & Cellular Therapy, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Joseph MaakaronBlood and Marrow Transplant & Cellular Therapy, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Armin RashidiBlood and Marrow Transplant & Cellular Therapy, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Jeffrey S MillerBlood and Marrow Transplant & Cellular Therapy, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
John E WagnerBlood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Bruce R BlazarBlood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Pamala A JacobsonExperimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.
Angela Panoskaltsis-MortariBlood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Daniel J WeisdorfBlood and Marrow Transplant & Cellular Therapy, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Margaret L MacMillanBlood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
University of Minnesota · USRush University · US

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Single Cell Analysis and ImmunogeneticsP01HL158505 · NHLBI · DANA-FARBER CANCER INST · PI Corey S Cutler · 2022 to 2026
$15.3M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory DiseaseR01HL155114 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, NOELLE, RANDOLPH J. · 2021 to 2024
$2.7M
NCI NIH HHS P01 CA065493NHLBI NIH HHS P01 HL158505NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL147324NHLBI NIH HHS R01 HL155114NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

Treatments that aid inflammation resolution, immune tolerance, and epithelial repair may improve outcomes beyond high-dose corticosteroids and other broad immunosuppressants for life-threatening acute graft-versus-host disease (aGVHD). We studied the addition of urinary-derived human chorionic gonadotropin/epidermal growth factor (uhCG/EGF; Pregnyl; Organon, Jersey City, NJ) to standard aGVHD therapy in a prospective Phase II clinical trial (ClinicalTrials.gov identifier NCT02525029). Twenty-two patients with Minnesota (MN) high-risk aGVHD received methylprednisolone 48 mg/m

Indexed as

Epidermal Growth FactorGraft vs Host DiseaseChorionic GonadotropinHumansImmune ToleranceProspective StudiesChorionic GonadotropinEpidermal Growth FactorAmphiregulinGVHDTissue repairTolerance

Identifiers

PMID37279855
PMCPMC11015887
OpenAlexW4379280160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.